Bristol-Myers Squibb Company (BMY)

49.23
NYSE : Health Care
Prev Close 55.49
Day Low/High 48.92 / 50.69
52 Wk Low/High 48.92 / 77.12
Avg Volume 10.09M
Exchange NYSE
Shares Outstanding 1.67B
Market Cap 92.74B
EPS 0.90
P/E Ratio 18.02
Div & Yield 1.56 (2.80%)

Latest News

Bristol-Myers Squibb And Ono Pharmaceutical Company Enter Settlement And License Agreement With Merck To Resolve PD-1 Antibody Patent Litigation

Bristol-Myers Squibb And Ono Pharmaceutical Company Enter Settlement And License Agreement With Merck To Resolve PD-1 Antibody Patent Litigation

Bristol-Myers Squibb Company (NYSE:BMY) and Ono Pharmaceutical Company, Ltd.

Stocks Rising as Donald Trump Inherits the White House

Stocks Rising as Donald Trump Inherits the White House

Stocks are higher on Friday after Donald Trump is sworn in as the 45th president of the United States.

Ready to Trade Bristol-Myers Squibb, Bank of America, CSX? Here's What to Know

Ready to Trade Bristol-Myers Squibb, Bank of America, CSX? Here's What to Know

Here's how to trade seven of the most active stocks on the market this week.

Jim Cramer Shares His Concerns About Bristol-Myers Squibb

Jim Cramer Shares His Concerns About Bristol-Myers Squibb

Jim Cramer looks at Bristol-Myers Squibb's Opdivo setback.

Stocks Come Off Highs as Trump Pledges to Rebuild America

Stocks Come Off Highs as Trump Pledges to Rebuild America

Stocks pare gains on Friday as Donald Trump is sworn in as 45th President of the United States.

Stock Futures Rise but in Hesitant Trading as Trump Prepares to Take Office

Stock Futures Rise but in Hesitant Trading as Trump Prepares to Take Office

Stock futures creep higher on Friday in hesitant trading ahead of the inauguration of President-elect Donald Trump.

Setback for Bristol-Myers on Lung Cancer Treatment Drugs

Setback for Bristol-Myers on Lung Cancer Treatment Drugs

Bristol-Myers Squibb suffers a setback in immunotherapy treatment for newly diagnosed lung cancer.

Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly

Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly

Bristol-Myers suffered another setback when the pharma giant said it would not seek accelerated approval for a combination of two immunotherapy drugs as a treatment for newly diagnosed lung cancer.

Bristol-Myers Squibb Provides Regulatory Update In First-line Lung Cancer

Bristol-Myers Squibb Provides Regulatory Update In First-line Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has decided not to pursue an accelerated regulatory pathway for the combination of Opdivo plus Yervoy in first-line lung cancer in the U.

Opdivo (nivolumab) Demonstrated Efficacy And Improved Survival In Patients With Previously Treated Advanced Gastric Cancer In A Randomized Phase 3 Study

Opdivo (nivolumab) Demonstrated Efficacy And Improved Survival In Patients With Previously Treated Advanced Gastric Cancer In A Randomized Phase 3 Study

Bristol-Myers Squibb Company (NYSE:BMY) announced today the results of ONO-4538-12 demonstrating Opdivo (nivolumab) significantly reduced the risk of death by 37% (HR 0.

Why Bristol-Myers Squibb May Be a Merger Target Soon

Why Bristol-Myers Squibb May Be a Merger Target Soon

Jana Partners' Barry Rosenstein recently acquired a large stake in Bristol-Myers.

Why Bristol-Myers Squibb May Be a Merger Target Soon

Why Bristol-Myers Squibb May Be a Merger Target Soon

The $101 billion market cap pharma could be put in play or targeted by an activist investor soon.

Bristol-Myers and AstraZeneca Take Beatings

Bristol-Myers and AstraZeneca Take Beatings

It happened in the wake of Merck's latest drug approval.

Closing Bell: Volkswagen Secures Plea Deal; Trump Triggers Biotech Selloff

Closing Bell: Volkswagen Secures Plea Deal; Trump Triggers Biotech Selloff

Wall Street secured gains again by late afternoon Wednesday in unpredictable trading following President-elect Donald Trump's first press conference since July.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)

Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)

Jim Cramer says he's focusing on health-care companies that will break news that moves stocks.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Bristol-Myers Squibb And GeneCentric Diagnostics Announce Exploratory Biomarker Research Collaboration

Bristol-Myers Squibb And GeneCentric Diagnostics Announce Exploratory Biomarker Research Collaboration

Bristol-Myers Squibb Company (NYSE:BMY) and GeneCentric Diagnostics, Inc.

Senate Dems, D.C. Watchdog Call for Investigation Into Trump HHS Pick Tom Price's Stock Portfolio

Senate Dems, D.C. Watchdog Call for Investigation Into Trump HHS Pick Tom Price's Stock Portfolio

Congressional Republicans who scrapped plans to overhaul the Office of Congressional Ethics might be regretting their decision. Senate Dems are asking for an investigation into HHS pick Tom Price.

Bristol-Myers Squibb Announces Immunotherapy Clinical Collaboration With Janssen To Evaluate Opdivo (nivolumab) In Combination With Darzalex (daratumumab)

Bristol-Myers Squibb Announces Immunotherapy Clinical Collaboration With Janssen To Evaluate Opdivo (nivolumab) In Combination With Darzalex (daratumumab)

Bristol-Myers Squibb Company (NYSE:BMY) today announced a new clinical research collaboration with Janssen Biotech, Inc.

Biotech Should Witness M&A's Return in 2017

Biotech Should Witness M&A's Return in 2017

Drug giants with money to spend and a friendlier regulatory environment should spur deals.

Bristol-Myers Squibb To Present At J.P. Morgan Healthcare Conference

Bristol-Myers Squibb To Present At J.P. Morgan Healthcare Conference

Bristol-Myers Squibb Company (NYSE: BMY) will present at the J.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Bristol-Myers Squibb To Take Part At The Goldman Sachs Healthcare CEOs Unscripted: A View From The Top

Bristol-Myers Squibb To Take Part At The Goldman Sachs Healthcare CEOs Unscripted: A View From The Top

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Goldman Sachs Healthcare CEOs Unscripted: A View from the TopĀ on Thursday, January 5, 2017, in Boston, Massachusetts.

Choppiness Usually Ends With Some Sort of Decline

Typically, the best way to get sentiment to turn is to take the indexes down.

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

A look back at the year's worth of Adam Feuerstein's biotech tweets.

Giovanni Caforio Named Chairman Of Bristol-Myers Squibb's Board Of Directors

Giovanni Caforio Named Chairman Of Bristol-Myers Squibb's Board Of Directors

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the company's Board of Directors has appointed Giovanni Caforio, M.